← Leaderboards
Wayne William Hancock
Children'S Hosp Of Philadelphia
$20,750,331
Attributed
$22,509,112
Total exposure
21
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,509,112 · 21
By mechanism
R01$16,251,654 · 11
P01$3,444,331 · 5
RC1$958,961 · 1
R21$832,500 · 1
R56$621,666 · 2
R43$400,000 · 1
Top collaborators
- John C Bucuvalas2 shared
- Matthew Howard Levine2 shared
- Veenu Aishwarya1 shared
- Hasina Hamilton Outtz1 shared
Most similar at Children'S Hosp Of Philadelphia
Same institution · by research overlap
- Daniel J. Campbell$19,196,457
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoCellsAutoimmunityIn VitroAffectHistonesRegulatory T-LymphocyteT-LymphocyteImmune ResponseProteinsImmuneRegulationIncidenceChronicBaseAcetylationResponseGene ExpressionPreventNovel TherapeuticsTransplantationMouse ModelInsightEnzymes
Grant awards (59)
Lymphatic Dysfunction and Development of Post-Transplant Obliterative Bronchiolitis$750,162
R01 · FY2025 · HL · contact PI
Estrogen and Serms as Therapy for Renal Ischemia Reperfusion Injury$703,985
R01 · FY2025 · DK
Estrogen and Serms as Therapy for Renal Ischemia Reperfusion Injury$704,454
R01 · FY2024 · DK
Pre-Transplant Monocyte HDAC6 Expression and Risk of Primary Graft Dysfunction in Clinical Lung Transplant Recipients$435,274
R01 · FY2024 · HL · contact PI
PROTAC Targeting of Tip60 in Syngeneic Cancer Models Using Cereblon Knock-in Mice$376,197
R01 · FY2024 · CA · contact PI
Pre-Transplant Monocyte HDAC6 Expression and Risk of Primary Graft Dysfunction in Clinical Lung Transplant Recipients$435,361
R01 · FY2023 · HL · contact PI
PROTAC Targeting of Tip60 in Syngeneic Cancer Models Using Cereblon Knock-in Mice$388,077
R01 · FY2023 · CA · contact PI
Pre-Transplant Monocyte HDAC6 Expression and Risk of Primary Graft Dysfunction in Clinical Lung Transplant Recipients$435,445
R01 · FY2022 · HL · contact PI
Evaluation of lead FANA oligos targeting FOXP3, with and without anti-PD-1 mAb, as an approach for cancer immunotherapy$400,000
R43 · FY2022 · CA
PROTAC Targeting of Tip60 in Syngeneic Cancer Models Using Cereblon Knock-in Mice$388,077
R01 · FY2022 · CA · contact PI
Pre-Transplant Monocyte HDAC6 Expression and Risk of Primary Graft Dysfunction in Clinical Lung Transplant Recipients$454,430
R01 · FY2021 · HL · contact PI
PROTAC Targeting of Tip60 in Syngeneic Cancer Models Using Cereblon Knock-in Mice$399,051
R01 · FY2021 · CA · contact PI
PROTAC Targeting of Tip60 in Syngeneic Cancer Models Using Cereblon Knock-in Mice$427,654
R01 · FY2020 · CA · contact PI
Class IIa HDAC and MEF2 Targeting to Promote Foxp3+ Treg Cell Functions$420,000
R01 · FY2020 · AI · contact PI
Class IIa HDAC and MEF2 Targeting to Promote Foxp3+ Treg Cell Functions$420,000
R01 · FY2019 · AI · contact PI
INHIBITION OF A TREG DEUBIQUITINASE, USP7, PROMOTES ANTI-TUMOR IMMUNITY$369,220
R01 · FY2019 · CA · contact PI
Class IIa HDAC and MEF2 Targeting to Promote Foxp3+ Treg Cell Functions$420,000
R01 · FY2018 · AI · contact PI
INHIBITION OF A TREG DEUBIQUITINASE, USP7, PROMOTES ANTI-TUMOR IMMUNITY$380,640
R01 · FY2018 · CA · contact PI
INHIBITION OF A TREG DEUBIQUITINASE, USP7, PROMOTES ANTI-TUMOR IMMUNITY$172,000
R01 · FY2018 · CA · contact PI
Class IIa HDAC and MEF2 Targeting to Promote Foxp3+ Treg Cell Functions$420,000
R01 · FY2017 · AI · contact PI
INHIBITION OF A TREG DEUBIQUITINASE, USP7, PROMOTES ANTI-TUMOR IMMUNITY$380,640
R01 · FY2017 · CA · contact PI
Class IIa HDAC and MEF2 Targeting to Promote Foxp3+ Treg Cell Functions$420,000
R01 · FY2016 · AI · contact PI
INHIBITION OF A TREG DEUBIQUITINASE, USP7, PROMOTES ANTI-TUMOR IMMUNITY$380,640
R01 · FY2016 · CA · contact PI
Foxp3+ Treg Cells & Primary Graft Dysfunction in Clinical Lung Tx Recipients$407,277
R01 · FY2015 · HL · contact PI
INHIBITION OF A TREG DEUBIQUITINASE, USP7, PROMOTES ANTI-TUMOR IMMUNITY$397,640
R01 · FY2015 · CA · contact PI
HAT Inhibition to Impair Foxp3+ Treg Function and Boost Anti-Tumor Immunity$343,724
R01 · FY2015 · CA · contact PI
Foxp3+ Treg Cells & Primary Graft Dysfunction in Clinical Lung Tx Recipients$405,278
R01 · FY2014 · HL · contact PI
HAT Inhibition to Impair Foxp3+ Treg Function and Boost Anti-Tumor Immunity$333,413
R01 · FY2014 · CA · contact PI
Foxp3+ Treg Cells & Primary Graft Dysfunction in Clinical Lung Tx Recipients$385,850
R01 · FY2013 · HL · contact PI
HAT Inhibition to Impair Foxp3+ Treg Function and Boost Anti-Tumor Immunity$323,100
R01 · FY2013 · CA · contact PI
Therapeutic effects of histone deacetylase inhibitors on FOXP3 Treg functions$482,526
P01 · FY2012 · AI · contact PI
Foxp3+ Treg Cells & Primary Graft Dysfunction in Clinical Lung Tx Recipients$456,242
R01 · FY2012 · HL · contact PI
HAT Inhibition to Impair Foxp3+ Treg Function and Boost Anti-Tumor Immunity$343,724
R01 · FY2012 · CA · contact PI
Therapeutic effects of histone deacetylase inhibitors on FOXP3 Treg functions$479,955
P01 · FY2011 · AI · contact PI
HAT Inhibition to Impair Foxp3+ Treg Function and Boost Anti-Tumor Immunity$377,474
R01 · FY2011 · CA · contact PI
ANTI-INFLAMMATORY EFFECTS OF TARGETING THE HDAC6/HSP90 PATHWAY$209,375
R56 · FY2011 · AI · contact PI
Calcineurin Inhibitor Minimization And Foxp3+ Tregs Post-Transplant$481,034
RC1 · FY2010 · DK · contact PI
Therapeutic effects of histone deacetylase inhibitors on FOXP3 Treg functions$460,664
P01 · FY2010 · AI · contact PI
Calcineurin Inhibitor Minimization And Foxp3+ Tregs Post-Transplant$477,927
RC1 · FY2009 · DK · contact PI
Therapeutic effects of histone deacetylase inhibitors on FOXP3 Treg functions$467,081
P01 · FY2009 · AI · contact PI
Therapeutic effects of histone deacetylase inhibitors on FOXP3 Treg functions$462,397
P01 · FY2008 · AI · contact PI
Therapeutic Effects of Histone Deacetylase Inhibitors on Foxp3 + Treg Functions$411,875
R01 · FY2008 · AI · contact PI
Allograft Homing and Function of Regulatory T Cells Post-Transplant$412,291
R56 · FY2007 · AI · contact PI
CD28/B7 Costimulation Blockade-Resistant Graft Rejection$402,977
R01 · FY2007 · AI · contact PI
CD28/B7 Costimulation Blockade-Resistant Graft Rejection$415,013
R01 · FY2006 · AI · contact PI
CD28/B7 Costimulation Blockade-Resistant Graft Rejection$425,000
R01 · FY2005 · AI
CD28/B7 Costimulation Blockade-Resistant Graft Rejection$425,000
R01 · FY2004 · AI
CD28/B7 Costimulation Blockade-Resistant Graft Rejection$425,000
R01 · FY2003 · AI
Modulation of Chemokine-Dependent Islet Injury$407,500
R21 · FY2003 · DK
Modulation of Chemokine-Dependent Islet Injury$425,000
R21 · FY2002 · DK
CORE--IMMUNOPATHOLOGY$211,312
P01 · FY2002 · DK
Core--immunopathology and molecular facility$0
P01 · FY2002 · AI
CORE--IMMUNOPATHOLOGY$211,312
P01 · FY2001 · DK
CORE--IMMUNOPATHOLOGY$180,000
P01 · FY2001 · DK
Core--immunopathology and molecular facility$0
P01 · FY2001 · AI
ANTIINFLAMMATORY EFFECTS OF PROTEIN C &THROMBOMODULIN$291,760
R01 · FY2000 · HL
CORE--IMMUNOPATHOLOGY OF CHRONIC ALLOGRAFT REJECTION FACILITY$184,511
P01 · FY2000 · AI
NUCLEAR FACTOR KAPPA BETA DEPENDENT GENES AND TRANSPLANT ARTERIOSCLEROSIS$184,511
P01 · FY2000 · AI
CORE--IMMUNOPATHOLOGY$120,062
P01 · FY2000 · DK